BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...
LifeVantage Corporation (Nasdaq: LFVN) is a pio...
Alpine is a development-stage specialty pharmaceutical company focused on discover...
Alpine is a development-stage specialty pharmac...
BioHealthonomics Inc. is a research and development biotechnology & healthcare com...
BioHealthonomics Inc. is a research and develop...
Tactile Medical is a leader in developing and marketing at-home therapy devices th...
Tactile Medical is a leader in developing and m...
We are a global medical technology company focused on the design, development and ...
We are a global medical technology company focu...
CONMED is a medical technology company that provides surgical devices and equipmen...
CONMED is a medical technology company that pro...
Join the National Investor Network and get the latest information with your interests in mind.